Erratum: Guidelines on the management of arterial hypertension and related comorbidities in Latin America (Journal of Hypertension (2017) 35 (1529-1545) DOI: 10.1097/HJH.0000000000001418);Guidelines on the management of arterial hypertension and related comorbidities in Latin America

Journal of Hypertension

Volumn 35, Issue 8, 2017, Pages 1529-1545

  Barbosa, Eduardo ^a   Coca, Antonio ^b   Lopez Jaramillo, Patricio ^c,d   Ramirez, Agustín J ^e   Sanchez, Ramiro A ^e   Zanchetti, Alberto ^f  

^a Moinhos de Vento Hospital   (Brazil)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Prediabetes y Diabetes   (Colombia)

^d School of Engineering Sciences and Industry   (Ecuador)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

comorbidities; guidelines; hypertension; Latin America

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLITAZONE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; COMORBIDITY; DIABETES MELLITUS; DIABETIC HYPERTENSION; DYSLIPIDEMIA; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; METABOLIC SYNDROME X; MONOTHERAPY; NON COMMUNICABLE DISEASE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SOUTH AND CENTRAL AMERICA; ARTERY; BLOOD PRESSURE; CHRONIC DISEASE; COMPLICATION; DIABETIC COMPLICATION; ETHNOLOGY; FEMALE; LIFESTYLE; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RISK;

ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; CHRONIC DISEASE; COMORBIDITY; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LATIN AMERICA; LIFE STYLE; METABOLIC SYNDROME; OBESITY; PERIPHERAL ARTERIAL DISEASE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK; STROKE;

EID: 85021794583     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001551     Document Type: Erratum

References (119)

1. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al., GBD 2013 Risk Factors Collaborators. Global, regional, national comparative risk assessment of 79 behavioural, environmental and occupational, metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:2287-2323.
2. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
4. Lopez-Jaramillo P, Molina de Salazar DI, Coca A, Zanchetti A. Manual Practico LASH de Diagnostico y Manejo de la Hipertension Arterial en Latinoamerica. 2013; http://www.documentoslash.org/es/.
5. Daz ME. Prevalence of hypertension in Latin America. In: Hernandez RH, Armas-Hernandez MJ, editors. Current advances in hypertension. Proceedings of the IV Latin American Congress on Hypertension-Latin American Society of Hypertension. Bologna: Medimond; 2005. pp. 1-8.
6. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the chronic care model. The new millennium. Health Aff 2009; 28:75-85.
7. Mengue SS, Bertoldi AD, Ramos LR, Farias MR, Oliveira MA, Tavares NU, et al. Acesso e uso de medicamentos para hipertensao arterial no Brasil. Rev Saude Publica 2016; 50 (Suppl 2):1s-9s.
8. Oliveira Araujo JL, Pereira MD, Del Fiol FS, Barberato-Filho S. Access to antihypertensive agents in Brazil: Evaluation of the 'Health Has No Price' program. Clin Ther 2014; 36:1191-1195.
9. Hernandez-Hernandez R, Silva H, Velasco M, Pellegrini F, Macchia A, Escobedo J, et al. Hypertension in seven Latin American cities: The Cardiovascular Risk Factor MultipleEvaluation in Latin America (CARMELA) study. J Hypertens 2010; 28:24-34.
10. Schargrodsky H, Hernandez-Hernandez R, Champagne BM, Silva H, Vinueza R, Silva Aycąguer LC, et al., CARMELA Study Investigators. CARMELA: Assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008; 121:58-65.
11. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S, PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, high-income countries. Am Heart J 2009; 158:1-7.
12. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al., PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, control of hypertension in rural and urban communities in high-, middle-, low-income countries. JAMA 2013; 310:959-968.
13. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117:743-753.
14. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart 2003; 24:987-1003.
15. Bryce-Moncloa A, Lara J, Cobos L, San-MartnM, et al.: Consenso para el control del riesgo cardiovascular en el Pacfico Sur (Ecuador, Peru y Chile). Colegio Panamericano de Endotelio, 2015, pg.: 16-27. Impreso en: IMPRESSO GRAFICA, Miraflores, Lima, Peru. Hecho el depo sito legal en la Biblioteca Nacional del Peru:N-2015-16031.
16. Lopez Jaramillo P, Sanchez RA, Diaz M, Cobos L, Bryce A, Parra-Carrillo JZ, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens 2013; 31:223-238.
17. Stahl CH, Lind M, Svensson AM, Gudbjornsdottir S, Martensson A, Rosengren A. Glycemic control and excess risk of ischemic and hemorrhagic stroke in patients with type 1 diabetes: A cohort study of 33 453 patients. J Intern Med 2016; doi:10.1111/joim.12572.
18. Alegre Diaz J, Harrington W, Lopez-Cervantes M, Gnatiuc L. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 2016; 17:1961-1971.
19. Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. Exp Clin Endocrinol Diabetes 2016; doi:10.1055/s-0042-117717.
20. Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: A metaanalysis. Clin Cardiol 2016; [Epub ahead of print]. doi: 10.1002/clc.22657.
21. Gandhi J, Dagur G, Warren K, Smith N, Khan SA. The role of sexual dysfunction and infertility on reproductive health in diabetics: Pathogenesis, evaluation, management. Curr Diabetes Rev 2016; Nov 22. [Epub ahead of print].
22. Khalil H. Diabetes microvascular complications-a clinical update. Diabetes Metab Syndr 2016; [Epub ahead of print]. doi: 10.1016/j.dsx.2016.12.022.
23. Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, Moustaid-Moussa N. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochem Biophys Acta 2016; [Epub ahead of print]. doi: 10.1016/j.bbadis.2016.07.019.
24. Holwerda SW, Vianna LC, Restaino RM, Chaudhary K, Young CN, Fadel PJ. Arterial baroreflex control of sympathetic nerve activity and heart rate in patients with type 2 diabetes. Am J Physiol Heart Circ Physiol 2016; 311:H1170-H1179.
25. Gupta S, Wang Z. Predictors of sleep disorders among patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2016; 10:213-220.
26. DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and diagnosing heart disease. 'A clinical perspective'. Heart Int 2014; 9:37-44.
27. Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309-312.
28. Sempertegui F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempertegui M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr 2011; 14:758-767.
29. Alvarez C, Salazar R, Galindez J, Rangel F, Castaneda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010; 14:256-263.
30. Bermudez V, Marcano RP, Cano C, Arraz N, Amell A, Cabrera M, et al. The Maracaibo city metabolic syndrome prevalence study: Design and scope. Am J Ther 2010; 17:288-294.
31. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndromein LatinAmerica and its association with sub-clinical carotid atherosclerosis: The CARMELA cross sectional study. Cardiovasc Diabetol 2009; 26:8-52.
32. Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr 2008; 8:1-6.
33. Royer M, Castelo-Branco C, Blumel JE, Chedraui PA, Danckers L, Bencosme A, et al., Collaborative Group for Research of the Climacteric in Latin America. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): Prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007; 10:164-170.
34. Garcia RG, Perez M, Maas R, Schwedhelm E, Boger RH, Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007; 122:176-178.
35. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
36. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, cardiovascular disease. J Clin Endocrinol Metab 2003; 88:2399-2403.
37. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes 2004; 53:2087-2094.
38. Spence JD. Cerebral consequences of hypertension. J Hypertens 1996; 14:S139-S145.
39. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al., INTERSTROKE Investigators. Risk factors for ischemic and intracerebral hemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376:112-123.
40. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al., Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-255.
41. Porcello Marrone LC, Diogo LP, de Oliveira FM, Trentin S, Scalco RS, et al. Risk factors among stroke subtypes Brazil. J Stroke Cerebrovasc Dis 2013; 22:32-35.
42. De Jesus Llibre J, Valhuerdi A, Fernandez O, Llibre JC, Porto R, Lopez AM, et al. Prevalence of stroke and associated risk factors in older adults in Havana city and Matanzas province, Cuba. MEDICC Rev 2010; 12:20-26.
43. Lanas F, Seron P, Lanas A. Cardiovascular disease in Latin America: The growing epidemic. Progr Cardiovasc Dis 2014; 57:262-267.
44. Manolio TA, Kronmal RA, Burke GL, Poirier V, O'Leary DH, Gardin JM, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: The Cardiovascular Health Study. Stroke 1994; 25:318-327.
45. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-952.
46. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al., INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: The INTERHEART Latin American study. Circulation 2007; 115:1067-1074.
47. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al., INTER-CHF Investigators. Heart failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. Int J Cardiol 2016; 204:133-141.
48. Rodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, et al. Left ventricular mass and ventricular remodelling among Hispanic subgroups compared with non-Hispanic blacks and whites MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 55:234-242.
49. Bocchi EA. The reality of heart failure in Latin America. J Am Coll Cardiol 2013; 62:949-958.
50. Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, et al. Race-ethnic disparities in the impact of stroke risk factors: The northern Manhattan stroke study. Stroke 2001; 32:1725-1731.
51. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA 1996; 275:1581-1589.
52. Textor S. Atherosclerotic renal artery stenosis: How big is the problem and what happens if nothing is done J Hypertens 2005; 23 (Suppl 3):s5-s13.
53. Lance D, Dworkin M, Elliott WJ. Secondary hypertension: Renovascular hypertension. In: Black H, Elliott WG, editors. Hypertension: A companion to Braunwald's Heart Disease. Philadelphia, PA: Saunders Elsevier; 2007. pp. 93-105.
54. Krumme W, Blum U, Schwertfeger E, Flugel P, Hollstin F, Schollmeyer P, et al. Diagnosis of renovascular disease by intra-and extrarenal Doppler scanning. Kidney Int 1996; 50:1288-1292.
55. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431-442.
56. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: A randomized trial. EssaiMulticentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823-829.
57. Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, Marinovich S, Fernandez S, Lugon J, et al. Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J 2014; 7:431-436.
58. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: A risk profile from the Framingham Heart Study. Circulation 1997; 96:44-49.
59. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, Quiles J, Guindo J, Soria F, et al. Prevalence and prognostic influence of peripheral arterial disease in patients 40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg 2008; 36:189-196.
60. Ingolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: A strong relationship to smoking and serum cholesterol the Reykjavik Study. J Clin Epidemiol 1994; 47:1237-1243.
61. Sanchez RA, Ayala M, Baglivo H, Velasquez C, Burlando G, Kohlmann O, et al., Latin America Expert Group. Latin American guidelines on hypertension. J Hypertens 2009; 27:905-922.
62. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359-1366.
63. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011; 8:686-693.
64. Longo D, Dorigatti F, Palatini P. Masked hypertension in adults. Blood Press Monit 2005; 10:307-310.
65. Ho JE, Larson MG, Ghorbani A, Cheng S, Coglianese EE, Vasan RS, Wang TJ. Long-term cardiovascular risks associated with an elevated heart rate: The Framingham Heart Study. J Am Heart Assoc 2014; 3:e000668.
66. Palatini P, AgabitiRosei E, Casiglia E, Chalmers J, Ferrari R, Grassi G, et al. Management of the hypertensive patient with elevated heart rate: Statement of the second consensus conference endorsed by the European Society of Hypertension. J Hypertens 2016; 34: 813-821.
67. Pickering TG, Hall JE, Appel LJ, Falkner BE, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161.
68. Kang YY, Li Y, Huang QF, Song J, Shan XL, Dou Y, et al. Accuracy of home versus ambulatory blood pressure monitoring in the diagnosis of white-coat and masked hypertension. J Hypertens 2015; 33:1580-1587.
69. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al., ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension Practice Guidelines for home blood pressure monitoring. J Human Hypertens 2010; 24:779-785.
70. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285-2295.
71. Grotto I, Huerta M, Sharabi I. Hypertension and socio-economic status. Curr Opin Cardiol 2008; 23:335-339.
72. Flescher NL, Diez Rux AV, Alazraqui M, Spinelli H. Social patterning of chronic disease risk factors in a Latin American city. J Urban Health 2008; 85:923-937.
73. Lopez-Jaramillo P, Coca A, Sanchez R, Zanchetti A. Is it time to reappraise blood pressure thresholds and targets Position Statement of the Latin American Society of Hypertension. Hypertension 2016; 68:257-262.
74. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
75. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
76. National Institute for Health and Clinical Excellence. Hypertension (CG127): Clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.
77. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15.
78. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 2. Effects at different baseline and achieved blood pressure levels. Overview and meta-analyses of randomized trials. J Hypertens 2014; 32: 2296-2304.
79. Lonn EM, Bosch J, Lopez Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood pressure lowering in intermediate risk persons without cardiovascular disease. N Engl J Med 2016; 374:2009-2020.
80. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al., The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-2116.
81. Parati G, Ochoa JE, Bilo G, Zanchetti A. SPRINT blood pressure; sprinting back to Smirk's basal blood pressure Hypertension 2017; 69:15-19.
82. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 7. Effects of more versus less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34:613-622.
83. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events-meta-analyses of randomized trials. J Hypertens 2016; 34:1451-1463.
84. Fagard RH. Exercise therapy in hypertensive cardiovascular disease. Prog Cardiovasc Dis 2011; 53:404-411.
85. Leong DP, Teo KK, Rangarajan S, Lopez Jaramillo P, Avezum A, Orlandini A, et al., Prospective Urban Rural Epidemiology (PURE) Study Investigators. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) Study. Lancet 2015; 836:266-273.
86. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 5. Head-to-head comparisons of various classes of antihypertensive drugs. Overview and meta-analyses. J Hypertens 2015; 33:1321-1341.
87. Morales Salinas A, Coca A, Olsen MH, Sanchez R, Sebba Barroso WK, Kones R, et al. Clinical perspective on antihypertensive drug treatment in adults with grade 1 hypertension and low-moderate risk: An international expert consultation. Curr Probl Cardiol 2017; [in publication].
88. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J Hypertens 2014; 32:2305-2314.
89. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: A metaanalysis. Hypertension 2010; 55:399-407.
90. Jamerson K, Weber MA, Bakris GL, Dahlof B, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
91. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
92. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
93. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, et al., Standardized Hypertension Treatment and Prevention Network. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: The Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens 2016; 18:1284-1294.
94. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al., PURE study Investigators. Availability and affordability of cardiovascular disease medicines and their effect on use in high income, middle income and low income countries: An Analysis of the PURE Study Data. Lancet 2016; 387:61-69.
95. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
96. [No authors listed]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703-713.
97. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
98. Cederholm J, Gudbjornsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM. Blood pressure and risk of cardiovascular disease in type 2 diabetes: Further findings from the Swedish National Diabetes Register (NDR-BP-II). J Hypertens 2012; 30:2020-2030.
99. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressurelowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus Overview and meta-analyses of randomized trials. J Hypertens 2017; 35:922-944.
100. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.
101. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 2000; 35:898-903.
102. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005; 112:969-975.
103. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813-1821.
104. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311-322.
105. Bonadonna RC, Borghi C, Consoli A, Volpe M. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutr Metab Cardiovasc Dis 2016; 26:759-766.
106. Son JW, Kim S. Dipeptidyl Peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: A tale of three studies. Diabetes Metab J 2015; 39:373-383.
107. Abdul-Ghani M, Del Prato S, Chilton R, De Fronzo RS. SGLT-2 inhibitors and cardiovascular risk: Lessons learned from the EMPAREG outcome Study. Diabetes Care 2016; 39:715-725.
108. Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: A post hoc analysis. Cardiovasc Diabetol 2017; 16:29.
109. Voto L.S. Hipertension en el embarazo, 1ra Edicion 2009, Corpus, ISBN:978-950-9030-69-75.
110. Gua para el diagno stico y tratamiento de la hipertension en el embarazo, Ministerio de Salud de la Nacion Argentina, Segunda edicion, 2010-2014.
111. Peek M, Shennan A, Halligan A, Lambert PC, Taylor DJ, de Swiet M. Hypertension in pregnancy: Which method of blood pressure measurement is most predictive of outcome Obstet Gynecol 1996; 88:1030-1033.
112. Ferrazzani S, Caruso A, De Carolis S, Martino IV, Mancuso S. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990; 162:366-371.
113. Wilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv 2002; 58:39-53.
114. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.
115. Authors. WHO recommendations for prevention and treatment of preeclampsia and eclampsia. Geneva, Switzerland: WHO; 2011; ISBN: 978 92 4 154833 5.
116. Redmond N, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension 2011; 57:383-389.
117. Fuchs F. Why do black Americans have higher prevalence of hypertension An enigma still unsolved. Hypertension 2011; 57:379-380.
118. Brewster LLM, Kleijnen J, van Montfrans G. Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database Syst Rev 2015;CD005183; doi:10.1002/14651858. CD005183.pub1.
119. Encuesta Demografica y de Salud Familiar. Instituto Nacional de Estadstica e Informatica. 2014; Available from: Http://proyectos. inei.gob.pe/endes/resultados.asp. [Cited 2015].